Sector portfolio · VC firm · United States
New Enterprise Associates' Pharma portfolio
New Enterprise Associates has backed 15 Pharma startups in rounds we track, $3.2B between them, shown by the stage each has reached. The best-funded is Resilience.
New Enterprise Associates's whole portfolioNew Enterprise Associates's profile
Funding by segment
- Series B$1.1B7
- Stage not reported$1.4B5
- Series C and later$737M3
Where they are based
- United States12$2.8B
- Canada3$417M
United States
CanadaFounded
1 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M1
- $10M to $50M2
- $50M to $250M7
- $250M to $1B5
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
14 of 15 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States12
- Canada3
Startups by country, 2 countries in all.
Segment by segment
Series B
7 startups · $1.1B raised
CRISPR THERAPEUTICSCRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.United States$550M
AllakosAllakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.United States$294MClementia PharmaceuticalsClementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders.Canada$93M
Comanche BiopharmaComanche Biopharma Corp.United States$75M
CerecorCerecor discovers, develops and commercializes neuroscience drugs.United States$71M
Amplyx PharmaceuticalsAmplyx focuses on developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immuUnited States$42M- EPESP PharmaE Shop Pharmacy is a discount worldwide pharmacy fulfillment service.United States$20M
Stage not reported
5 startups · $1.4B raised
ResilienceResilience is a cyber risk company based in San Francisco, founded in 2016 by experts from military intelligence, insurance, and technology.United States$860M
Aurinia PharmaceuticalsAurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.Canada$255M
Zosano PharmaZosano Pharma (ZSAN) is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics wUnited States$159M
Vitae PharmaceuticalsVitae Pharmaceuticals is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class cUnited States$79M
NexImmuneNexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.United States$8.9M
Series C and later
3 startups · $737M raised
Zenas BioPharmaZenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.United States$420M
ORIC PharmaceuticalsORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.United States$248M
Inversago PharmaInversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonistsCanada$69M
How this map is made. Every startup here works in Pharma and has raised money in a round we track that names New Enterprise Associates as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like New Enterprise Associates?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.